Dr. Oh on Remaining Challenges in mHSPC

William K. Oh, MD
Published: Friday, Dec 06, 2019



William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai Hospital, discusses remaining challenges in metastatic hormone-sensitive prostate cancer (mHSPC).
 
Although moving effective treatment options from later-line settings to earlier settings has proven to be beneficial for patients, doing so can leave patients who progress without options, says Oh.
 
The key challenge is that cancer will eventually develop resistance to available therapies, adds Oh. Investigators do not fully understand mechanisms of resistance in mHSPC, and therefore, are unsure why some patients progress.
 
In order to develop effective treatments targeting resistance pathways in mHSPC, a comprehensive understanding of the disease biology will be critical going forward, concludes Oh.
SELECTED
LANGUAGE


William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai Hospital, discusses remaining challenges in metastatic hormone-sensitive prostate cancer (mHSPC).
 
Although moving effective treatment options from later-line settings to earlier settings has proven to be beneficial for patients, doing so can leave patients who progress without options, says Oh.
 
The key challenge is that cancer will eventually develop resistance to available therapies, adds Oh. Investigators do not fully understand mechanisms of resistance in mHSPC, and therefore, are unsure why some patients progress.
 
In order to develop effective treatments targeting resistance pathways in mHSPC, a comprehensive understanding of the disease biology will be critical going forward, concludes Oh.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x